The drug ivermectin is one example. It’s gotten a lot of attention in recent years, but is not approved to treat any cancer ...

Hidradenitis suppurativa is a debilitating, chronic inflammatory disorder where physical examination often fails to capture ...

This guide breaks down how to prepare for an HS appointment so your treatment plan reflects more than just today's flare.

Dermatologists say managing HS-prone skin isn't about harsh products or over-cleansing-it's about reducing irritation and ...

There’s nothing more alarming than finding out your skin has a case of mistaken identity. You go years convinced you have ...

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting ...

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

Researchers are testing CAR T-cell therapy as a treatment for lupus, Graves’ disease and other conditions in which the body’s ...

As rheumatologists prepare for EULAR 2026, Clinical Trials Arena takes a look at the most promising drugs in late-stage development for PsA.

Arcutis Biotherapeutics is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, ...

COSENTYX offers growth opportunities due to a large patient base fueling recurring revenue, robust global demand, double-digit growth, and an expanding label across multiple inflammatory conditions.

Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time ...